Melanoma Trials Should Allow Intron A-Naïve Patients, Advisory Cmte. Says
Executive Summary
Enrollment in melanoma drug trials should not be restricted to patients who have failed interferon alfa therapy, FDA's Oncologic Drugs Advisory Committee concluded Feb. 27
You may also be interested in...
Will Weak Standard Of Care Lower Approval Bar For PegIntron For Melanoma?
FDA may be more likely to approve Schering-Plough's PegIntron for melanoma based on a modest improvement in relapse-free survival, without an effect on overall survival, with support from its Oncologic Drugs Advisory Committee that the survival advantage for the standard of care - Schering's own Intron A - is questionable
Will Weak Standard Of Care Lower Approval Bar For PegIntron For Melanoma?
FDA may be more likely to approve Schering-Plough's PegIntron for melanoma based on a modest improvement in relapse-free survival, without an effect on overall survival, with support from its Oncologic Drugs Advisory Committee that the survival advantage for the standard of care - Schering's own Intron A - is questionable
Melacine Relapse-Free Survival Endpoint Could Give Inconclusive Result
Use of relapse-free survival as a primary endpoint in studies of Corixa's melanoma vaccine Melacine would produce an ambiguous efficacy result, FDA's Oncologic Drugs Advisory Committee suggested